ANPD001 was well tolerated with no major safety issues in low-dose cohort Patients showed early improvements in patient-reported and clinician-re...
Lantheus Holdings, Inc.the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better ...
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, toda...
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...
Intuitive , a global leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), announced the publication of two st...
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show ...
Long COVID or post COVID-19 syndrome, is a clinical entity observed in certain patients wherein symptoms of illness persist for at least several week...
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform&tra...
HNL Lab Medicine, in partnership with Northampton County, is making it easier for families to access lead testing for children. Lead exposure remains a ser...
Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown to De...
Artificial intelligence streamlines the optimisation of bioprinting parameters for oral soft tissue grafts, reducing time and resourc...
Novo Nordisk announced new findings from the retrospective, observational SCORE study, demonstrating that treatment with semaglutide 2.4 mg was associate...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. D...
© 2025 Biopharma Boardroom. All Rights Reserved.
